Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.55 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.55 |
| ▸ | FER | P16591 | 1/20 | 0.55 |
| ▸ | LTK | P29376 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8123268 | 0.84 | LRRK2 (0.55) | LRRK2ACVR1PDGFRAFERLTK | |
| SCHEMBL17254632 | 0.81 | LRRK2 (0.38) | LRRK2ACVR1PDGFRAFERLTK | |
| SCHEMBL21151025 | 0.78 | GAA (0.43) | LRRK2ACVR1PDGFRAFERLTK | |
| SCHEMBL19543486 | 0.76 | ALDH1A1 (0.32) | LRRK2ACVR1PDGFRAFERLTK | |
| SCHEMBL2420711 | 0.75 | LRRK2 (0.90) | LRRK2ACVR1PDGFRAFERLTK | |
| SCHEMBL366728 | 0.75 | — | — | |
| SCHEMBL26678234 | 0.73 | DAO (0.54) | LRRK2ACVR1PDGFRAFERLTK | |
| SCHEMBL27425410 | 0.72 | LRRK2 (0.74) | LRRK2ACVR1PDGFRAFERLTK | |
| SCHEMBL1368292 | 0.72 | LRRK2 (1.00) | LRRK2ACVR1PDGFRAFERLTK | |
| SCHEMBL27980501 | 0.72 | LRRK2 (0.82) | LRRK2ACVR1PDGFRAFERLTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| EP-4218833-A1 | LABELING OF ANTIBODIES | Whitehead Institute for Biomedical Research (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023065137-A1 | SITE-SPECIFIC GLYCOPROTEIN CONJUGATES AND METHODS FOR MAKING THE SAME | GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) | 2023-04-27 | — | — | WO | disclosed |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20230035986-A1 | NOVEL CROSSLINKED ALGINIC ACID | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-02 | — | — | US | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| WO-2021011927-A1 | COMPLEMENT INHIBITOR DOSING REGIMENS | APELLIS PHARMACEUTICALS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2019118938-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-9987373-B2 | Modified glycoprotein, protein-conjugate and process for the preparation thereof | SYNAFFIX B.V. (NL) | 2018-06-05 | — | — | US | disclosed |
| US-20170326258-A1 | CONTRAST AGENTS BASED ON LONG-LIVED NUCLEAR SINGLET STATES AND RELATED METHODS | DUKE UNIVERSITY | 2017-11-16 | — | — | US | disclosed |
| US-9642924-B2 | Contrast agents based on long-lived nuclear singlet states and related methods | DUKE UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-9599628-B2 | Small molecule-dependent split aptamer ligation | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016050209-A1 | HETEROFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE, PREPARATION METHOD, AND BIO-RELATED SUBSTANCE | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050210-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| US-20150064113-A1 | CONTRAST AGENTS BASED ON LONG-LIVED NUCLEAR SINGLET STATES AND RELATED METHODS | DUKE UNIVERSITY | 2015-03-05 | — | — | US | disclosed |
| US-8703936-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140045207-A1 | COMPOSITIONS AND METHODS FOR MODIFICATION OF BIOMOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-13 | — | — | US | disclosed |
| US-8519122-B2 | Compositions and methods for modification of biomolecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-27 | — | — | US | disclosed |
| WO-2011113065-A2 | PEGYLATED POLYPLEXES FOR POLYNUCLEOTIDE DELIVERY | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2011-09-15 | — | — | WO | disclosed |
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326258-A1 | CONTRAST AGENTS BASED ON LONG-LIVED NUCLEAR SINGLET STATES AND RELATED METHODS | OAT, RXFP1, RXFP2 | LRRK2 695/4885ACVR1 3615/4885PDGFRA 3890/4885 |
| US-20110207147-A1 | Compositions and Methods for Modification of Biomolecules | PTMS, APEX1, ALG1 | LRRK2 4150/4885ACVR1 2323/4885PDGFRA 1317/4885 |
| US-20150064113-A1 | CONTRAST AGENTS BASED ON LONG-LIVED NUCLEAR SINGLET STATES AND RELATED METHODS | OAT, RXFP1, RXFP2 | LRRK2 695/4885ACVR1 3615/4885PDGFRA 3890/4885 |
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL23R | LRRK2 1360/4885ACVR1 694/4885PDGFRA 2611/4885 |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | LRRK2 2643/4885ACVR1 3899/4885PDGFRA 2607/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | LRRK2 1114/4885ACVR1 704/4885PDGFRA 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.